Klonetics is pleased to announce the appointment of Natasha Shumka as the company's new Chief Operating Officer (COO), effective immediately. Natasha, who has been an invaluable member of the Klonetics team as the Quality Assurance Person (QAP) and Chief Strategy Officer (CSO), will now take on this pivotal leadership role.
In her new capacity as COO, Natasha will assume responsibility for guiding and enhancing the company's operational functions. Her extensive experience with Global cannabis certifications, dedication to quality, and visionary approach make her the ideal candidate to lead Klonetics into a new era of growth and efficiency.
Natasha brings a wealth of expertise to her role as COO. Her previous positions within the company have allowed her to intimately understand Klonetics' operations, strategy, and culture. This familiarity positions her to make immediate and impactful contributions to the organization.
Natasha's primary focus as Chief Operating Officer will be to optimize operational efficiency, foster clear and effective communication channels, and ensure that the company's objectives are not only met, but exceeded. Her commitment to excellence and her ability to inspire and lead teams will play a crucial role in Klonetics' continued success.
Natasha is currently in the midst of pursuing her QAGMP (Quality Assurance and Good Manufacturing Practices) diploma. Her goal is to complete this program successfully, and her efforts are all part of a broader plan to obtain Klonetic GMP (Good Manufacturing Practices) approval. This approval is significant because it will enable Klonetic to expand its international relationships in the cannabis industry. By ensuring high-quality production and compliance with internationally recognized standards, Natasha's diploma and her dedication to GMP will play a pivotal role in Klonetic's efforts to establish itself as a reputable and trusted player in the global cannabis market.
Natasha Shumka's appointment as COO marks an exciting chapter in Klonetics' journey, and the company looks forward to achieving new goals, both here and abroad.
Please join us in congratulating Natasha Shumka on her well-deserved promotion to Chief Operating Officer at Klonetics.
This three-year project aims to develop the optimal media formulations and transformation process to generate the highest-value cannabis plants in the market. We have examined the response of different cannabis genotypes to tissue culture media formations to develop tissue culture media formulations tailored for cannabis genotypes. We will be evaluating upon flowering of the rooted clones of the selected tissue culture plants, flowers should have equal to or better yield and potency than traditional clone production and cultivation of cannabis plants.
Another goal of this project is to develop a genetic transformation procedure for cannabis from callus and/orprotoplast regeneration optimization. This protocol will be used to increase pathogen resistance and improve quality traits like yield in cannabis plants.
Abstract: First, the project will focus on the genetic structure of a subset of Klonetic's extensive germplasm collection by conducting a large genotyping-by-sequencing (GBS) experiment and single nucleotide polymorphism (SNP) data analyses. Second, the project will perform phenotypic analyses at the CLS (Canadian Light Source) to quantify important biochemical and agronomic traits associated with trichomes and seed formation.
Description: Due to longstanding restrictions, our basic knowledge of Cannabis is far behind other crops (Clarke and Merlin 2017). Hence, many of the claims made by the industry regarding the various applications of Cannabis require advanced molecular, pharmaceutical, and agronomic research, all of which require an in-depth understanding of its evolutionary history, genetic structure, biochemical variability, and reproductive diversity. This research proposed here provides a roadmap combining modern genomics tools to establish a solid business model for cannabis genetic improvement to cater to future needs of the medical and recreational market in Canada.
Abstract: An integrative research project aimed at studying the pollen generated by a core set of Cannabis accessions is proposed The project will develop phenotypic analyses of pollen at the CLS whereby both surface and internal structures can be qualified and quantified. The project will focus on identifying X and Y chromosomes carrying pollen, as this could be used in a sorting procedure for the directed breeding of female plants.
Description: Medicinal cannabis is a treasure trove of phytochemicals with more than 110 different cannabinoids, terpenes, and flavonoids. Major phytoactive compounds of interest are delta-9 tetrahydrocannabinolic acid (THCA) and cannabidolic acid (CBDA) for their medicinal effects. Varying profiles of THC, CBD, and terpenes with a range of 20-30% total cannabinoids in cannabis products provide numerous opportunities for treating different diseases (medicinal applications) and various organoleptic properties in combination with THC (recreational applications). Most of the traditional cannabis breeding in North America used hybrid or varietal approaches, whereas little efforts have been made to apply modern genomics tools and breeding methods for cannabis genetic improvement and innovation.
All Rights Reserved | Klonetics Plant Science Inc.